tiprankstipranks
Trending News
More News >

Thiogenesis Expands Phase 2 MELAS Trial with New French Site

Story Highlights
Thiogenesis Expands Phase 2 MELAS Trial with New French Site

Don’t Miss TipRanks’ Half-Year Sale

Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has issued an update.

Thiogenesis Therapeutics Corp has announced the activation of its second clinical site in France for its Phase 2 trial of TTI-0102, targeting MELAS, a serious mitochondrial disorder. This expansion marks a significant milestone, with the company surpassing the patient enrollment threshold for a planned interim analysis. The trial aims to evaluate the safety and efficacy of TTI-0102, a promising candidate for treating mitochondrial dysfunction, potentially impacting the company’s positioning in the biopharmaceutical industry and offering hope for patients with unmet medical needs.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It specializes in developing sulfur-based therapeutics aimed at treating serious pediatric and inherited mitochondrial diseases. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. Its lead product candidate, TTI-0102, is a prodrug designed to address challenges associated with first-generation thiol-based drugs.

Average Trading Volume: 33,000

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$37.05M

See more data about TTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1